U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C6H14N2O2.C2H4O2
Molecular Weight 206.2395
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LYSINE ACETATE

SMILES

CC(O)=O.NCCCC[C@H](N)C(O)=O

InChI

InChIKey=RRNJROHIFSLGRA-JEDNCBNOSA-N
InChI=1S/C6H14N2O2.C2H4O2/c7-4-2-1-3-5(8)6(9)10;1-2(3)4/h5H,1-4,7-8H2,(H,9,10);1H3,(H,3,4)/t5-;/m0./s1

HIDE SMILES / InChI
Molecular Formula C2H4O2
Molecular Weight 60.052
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C6H14N2O2
Molecular Weight 146.1876
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/npp/lysine.html | https://www.ncbi.nlm.nih.gov/pubmed/26252373

Lysing is an essential basic amino-acid encoded by codone AAA and AAG, and used in the biosynthesis of proteins. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken. In a clinical study lysine supplements was found to be an effective for reduction of occurrence, severity and healing time for recurrent HSV infection, however Cochrane Review concluded that the evidence is insufficient. Lysine was investigated for improving anxiety, ameliorating angina prectoris. Lysine acetylsalicylate has been used to treat pain and to detoxify the body after heroin use. Lysine clonixinate has been used for its analgesic properties for the treatment of migraine headaches and other painful conditions. However, limited clinical trials exist for these conditions.

CNS Activity

Originator

Drechsel, H.
8
Curator's Comment: Lysine was first isolated from casein (a milk phosphoprotein) in 1889 by the German dentist Heinrich Drechsel

Approval Year

1971
86
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Natural Metabolite
L-LYSINE MONOHYDRATE

Approved Use

Lysine has been studied for the prevention and treatment of herpes infections and cold sores.
Primary
Natural Metabolite
L-LYSINE MONOHYDRATE

Approved Use

Lysine supplements may relieve effort-related angina pectoris.
Primary
Natural Metabolite
L-LYSINE MONOHYDRATE

Approved Use

Lysine increases the intestinal absorption and reduces the renal elimination of calcium.
Primary
Natural Metabolite
L-LYSINE MONOHYDRATE

Approved Use

Lysine is believed to exert anxiolytic effects by acting as a partial serotonin receptor 4 antagonist and as a partial benzodiazepine agonist
Palliative
Natural Metabolite
L-LYSINE MONOHYDRATE

Approved Use

Lysine acetylsalicylate has been used to detoxify the body after heroin use.
Primary
Approved
8429
NEOPROFEN

Approved Use

NeoProfen is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA.

Launch Date

2006
PubMed

PubMed

TitleDatePubMed
A systematic approach to the analysis of protein phosphorylation.
2001 Apr
Translational extracts active biologically in vitro obtained from eukaryotic monolayer cells: a versatile method for viral RNA studies.
2001 Apr
Properties of microtubules assembled from mammalian tubulin synthesized in Escherichia coli.
2001 Apr 17
Peflin and ALG-2, members of the penta-EF-hand protein family, form a heterodimer that dissociates in a Ca2+-dependent manner.
2001 Apr 27
Efficient preparation of natural and synthetic galactosides with a recombinant beta-1,4-galactosyltransferase-/UDP-4'-gal epimerase fusion protein.
2001 Apr 6
Biochemical and functional characterization of a molecule expressed by a subset of thymic medullary epithelial cells.
2001 Feb
In vivo distribution and speciation of [114mIn]InCl3 in the Wistar rat.
2001 Feb
L-lysine reduces nonenzymatic glycation of glomerular basement membrane collagen and albuminuria in diabetic rats.
2001 Feb
Hydrolysed protein accelerates the gastrointestinal transport of formula in preterm infants.
2001 Feb
Development of xylose-fermenting yeast Pichia stipitis for ethanol production through adaptation on hardwood hemicellulose acid prehydrolysate.
2001 Feb
Two conserved lysines at the 50/20-kDa junction of myosin are necessary for triggering actin activation.
2001 Feb 2
Increased stability of nucleophosmin/B23 in anti-apoptotic effect of ras during serum deprivation.
2001 Jan
Continuous cell introduction for the analysis of individual cells by capillary electrophoresis.
2001 Jan 1
Hsp90 regulates p50(cdc37) function during the biogenesis of the activeconformation of the heme-regulated eIF2 alpha kinase.
2001 Jan 5
XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
2001 Mar 1
Patents

Patents

03984430
8
04113858
8
04230696
8
04239771
12
04400379
8
JPS55105649A
8
JPS61140552A
12
JPS6153248A
8
JPS6153249A
8

Sample Use Guides

In Vivo Use Guide
Lysin is an essential amino-acid. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken.
Route of Administration: Oral
In Vitro Use Guide
In the in vitro study of herpes simplex virus (HSV) growth in tissue culture, arginine deficiency suppressed HSV growth. Maximum herpes growth (as measured by plaques counting) was observed in flasks, containing 10-20 ug/ml of arginine. The addition of 50 ug/ml of lysine to the flasks containing 2.5 and 5.0 ug/ml of arginine reduced the number of viable plaque-forming units (PFU) from 3300 and 48800 to less than 10.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:20:00 GMT 2023
Edited
by admin
on Fri Dec 15 15:20:00 GMT 2023
Record UNII
TTL6G7LIWZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LYSINE ACETATE
EP   II   MART.   USP   VANDF   WHO-DD  
Common Name English
LYSINE, L-, MONOACETATE
Common Name English
L-LYSINE ACETATE
JAN   USP-RS  
Common Name English
L-LYSINE ACETATE [USP-RS]
Common Name English
LYSINE ACETATE [USP MONOGRAPH]
Common Name English
LYSINE ACETATE [EP IMPURITY]
Common Name English
L-LYSINE ACETATE [JAN]
Common Name English
L-LYSINE MONOACETATE
Common Name English
LYSINE ACETATE [MART.]
Common Name English
LYSINE ACETATE [II]
Common Name English
LYSINE ACETATE [EP MONOGRAPH]
Common Name English
Lysine acetate [WHO-DD]
Common Name English
LYSINE (AS ACETATE)
Common Name English
Code System Code Type Description
DAILYMED
TTL6G7LIWZ
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
PRIMARY
EVMPD
SUB127497
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
PRIMARY
ChEMBL
CHEMBL2104640
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
CONCEPT Dietary Supplement
SMS_ID
100000091744
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
PRIMARY
DRUG BANK
DBSALT001763
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
PRIMARY
FDA UNII
TTL6G7LIWZ
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
PRIMARY
PUBCHEM
104152
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
PRIMARY
RS_ITEM_NUM
1371501
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
PRIMARY
ECHA (EC/EINECS)
260-664-4
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
PRIMARY
RXCUI
6537
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
PRIMARY RxNorm
DRUG CENTRAL
4453
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
PRIMARY
CAS
57282-49-2
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
PRIMARY
EVMPD
SUB127496
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
PRIMARY
EVMPD
SUB21782
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
PRIMARY
NCI_THESAURUS
C66045
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
PRIMARY
EPA CompTox
DTXSID80886223
Created by admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
PRIMARY
Related Record Type Details
Structure of LYSINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ARGININE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
Structure of ASPARTIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
Structure of VALINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
Structure of IRON
IMPURITY -> PARENT
EP
Structure of SULFATE ION
IMPURITY -> PARENT
EP
Structure of GLUTAMIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
Structure of CHLORIDE ION
IMPURITY -> PARENT
EP
Structure of AMMONIUM CATION
IMPURITY -> PARENT
EP
Structure of ALANINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
Structure of ORNITHINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
Related Record Type Details
Structure of LYSINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966